+
Discussion
n Conservative estimates at all
stages of modelling.
n Most of the underlying patient
& cost data is robust.
n This is the only method to
estimate cost-effectiveness.
n First study of its kind in NZ.
n Modelling relies on numerous
assumptions & estimates.
n Transmission modelling was only
for MSM.
n Assumes everyone will be offered
& accept a single test.
n Undiagnosed people are not
included in the study.
n Costs & savings are not
experienced by the same
stakeholder at the same time.
n Costs are likely to change.
n Only applies to ADHB population.
n Does not account for long-term
effects on HIV incidence.
Strengths Limitations